세계 헌팅턴병 치료 시장은 2025-2032년의 예측 기간 동안 연평균 12.45%의 연평균 복합 성장률(CAGR)을 나타내고, 2024년 5억 956만 달러에서 2032년 13억 278만 달러에 달할 것으로 예측됩니다. UC Davis Health(캘리포니아 대학교)의 추정에 따르면, 헌팅턴병 환자 수 증가, 의약품 및 치료법에 대한 투자 증가, 헌팅턴병에 대한 인식 제고 이니셔티브 증가, 의학 연구의 급속한 발전 등이 이 시장의 성장을 뒷받침하고 있습니다. 헌팅턴병은 전 세계적으로 약 1만 명 중 1명이 앓고 있습니다. 최근 유전자 치료와 RNA 치료의 발전도 시장 확대에 힘을 보태고 있습니다.
또한, 정부 및 비영리 단체는 환자와 보호자 간의 협력 관계를 구축하여 임상시험에 대한 인식을 높이고 있습니다. 이러한 노력은 임상시험 참여율을 높일 뿐만 아니라 의약품 개발 일정을 앞당기고 있습니다. 또한, 진행 중인 임상 연구와 신경 퇴행성 진단 약물의 발전에 대한 의료진의 인식이 높아지면서 시장 성장을 가속하고 있습니다. 질병 변형 치료에 대한 투자 증가와 희귀질환 관리에 대한 정부의 지원 증가도 시장 확대에 기여하고 있습니다.
적용되는 모든 지역 및 국가에 대해 모든 부문이 제공됩니다.
상기 기업은 시장 점유율 순서가 아니며, 분석 작업중에 입수한 정보에 따라서 변경될 가능성이 있습니다.
Global Huntington's disease treatment market is projected to witness a CAGR of 12.45% during the forecast period 2025-2032, growing from USD 509.56 million in 2024 to USD 1302.78 million in 2032. The market's growth is supported by the rising cases of Huntington's disease, increasing investments towards pharmaceutical products and therapies, rising initiatives to increase awareness about the condition, and rapid advancements in medical research. As per the estimates of UC Davis Health (University of California), Huntington's disease affects about 1 in 10,000 people across the globe. Recent advancements in gene therapies and RNA therapeutics are also supporting the market's expansion.
Additionally, government and nonprofit organizations are fostering collaborations and clinical trial awareness among patients and caregivers. These efforts are not only improving trial participation rates but also accelerating drug development timelines. The market's growth is also driven by the increasing awareness among medical professionals about the ongoing clinical research and advancements in neurodegenerative diagnostics. Increasing investments in disease-modifying therapies coupled with the rising government support for the management of rare diseases is also contributing towards the market's expansion.
Advancements in Early Disease Detection and Treatment Support Market Growth
Early diagnosis and intervention are essential for the management of neurodegenerative disorders such as Huntington's disease. Modern testing techniques aid in the identification of individuals carrying Huntington's disease gene mutation, even before the occurrence of symptoms. This early identification for genetic counseling, clinical monitoring, and enrollment in clinical trials in a time-efficient manner. This in turn is allowing pharmaceutical companies to develop novel drugs, that are able to halt or slow the progression of the disease, providing lucrative growth opportunities for the market. For instance, in February 2025, Latus Bio, Inc. released data in support of its preclinical gene therapy program for Huntington's disease. The company introduced a new computational model for predicting the effects of the knockdown of MSH3 on reducing somatic instability. The company aims to use its AAV-DB-3 capsid variant for delivering an engineered mRNA to reduce the MSH3 in the cells that are affected by Huntington's disease.
Regulatory Approvals Support Market Expansion
Increasing regulatory support and approvals are propelling the market's expansion as they accelerate the adoption and accessibility of new therapeutic solutions. Regulatory bodies such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) are granting regenerative medicine advanced therapy and breakthrough therapy to promising candidates to ensure the availability of advanced therapies and incentivize the leading pharmaceutical companies to invest in Huntington's disease treatments. The provision of such designations facilitates faster drug development and review, ensuring the entry of innovative treatments. For instance, in April 2025, the US FDA granted breakthrough therapy designation to AMT-130 for treating Huntington's disease. Unlike current therapies available in the market, AMT-130 aims to address the underlying genetic cause of the condition and provide long-term solutions for Huntington's. As new drugs and gene therapies progress through clinical stages, the market is expected to expand rapidly, due to improved clinical outcomes and patient access.
Hospital Pharmacies Hold Significant Share of the Market
The segment's dominance is supported by the central role played by hospital pharmacies in the management of complex diseases such as Huntington's disease. A large portion of Huntington's disease medications, including deutetrabenazine and tetrabenazine, often necessitate close medical supervision and are prescription-only. Hospital pharmacies are well-equipped to ensure that both outpatients and inpatients have access to the necessary drugs and are often under the care of multidisciplinary teams such as genetic counselors, neurologists, and psychiatrists. Moreover, hospital pharmacies offer comprehensive services including medication monitoring, management of side effects, and adjustments to treatment regimens, which are crucial for Huntington's disease patients who may experience rapid changes in symptoms.
Meanwhile, leading hospital pharmacies are focusing on expanding their market presence, contributing to the segment's expansion. For instance, in March 2025, Apollo HealthCo Ltd, operator of the online platform Apollo 24/7 and Apollo Pharmacy, announced the expansion of its offline hospital pharmacy network in Bengal, India.
North America Holds a Major Market Share
The region's dominance can be attributed to the strong presence of leading pharmaceutical companies, high investments in research activities, and increasing cases of Huntington's disease in countries such as the United States and Canada. As per the estimates of the Huntington's Disease Society of America, approximately 41,000 Americans have Huntington's, and 200,000 Americans are at risk of inheriting the disease.
The market also benefits from favorable reimbursement policies and high levels of awareness among clinicians and the general population. The US FDA's stance on gene therapies and orphan drugs incentivizes companies to pursue treatments for Huntington's disease. Furthermore, organizations such as Huntington's Disease Society of America and the Hereditary Disease Foundation play a key role in advocacy, funding, and education. Canada, too, is witnessing a rise in Huntington's disease research with several centers of excellence and registry programs promoting real-world data collection. The region also benefits from numerous clinical trials and significant investments in neurodegenerative diseases.
Impact of the U.S. Tariffs on Global Huntington's Disease Treatment Market
The financial strain from the tariffs may divert resources away from research and development activities, forcing companies to scale back on or postpone clinical trials for Huntington's disease therapies due to rising operational costs. This could result in delays in the availability of novel therapeutic solutions and could slow the progress of promising treatments, including gene therapies, which are currently under various stages of development. In response to the tariffs, leading pharmaceutical companies are considering reshoring their manufacturing sites to the United States and diversifying their supply chains. The uncertainties surrounding the trade policies are also deterring investments in Huntington's research, impacting the market's expansion.
Key Players Landscape and Outlook
The key players in the market are actively focusing on developing novel therapeutic solutions that target the root cause of the disease and its progression and provide symptomatic relief. Additionally, the companies are also engaging in mergers and acquisitions to enhance their neurodegenerative pipeline. For instance, in December 2024, H. Lundbeck A/S completed the acquisition of Longboard Pharmaceuticals, Inc., allowing the company to expand its Huntington's portfolio. With Lundbeck's established expertise in neurology and global reach, Longboard's neflamapimod can be efficiently developed, commercialized, and made accessible to a broader patient base. Such acquisitions are expected to support the leading players in the market in expanding their customer base and strengthening their position in the market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.